**Charity Registration No. 800733**
**Company Registration No. 02229663 (England and Wales)**
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION**
_**IMPROVING LIVES BY SUPPORTING PROFESSIONALS IN THE DELIVERY OF KIDNEY CARE & RESEARCH**_
## **(A COMPANY LIMITED BY GUARANTEE)**
**ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021**
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) CONTENTS**
||**Page**|
|---|---|
|Trustees report|1 - 11|
|Independent auditor's report|12 - 15|
|Statement of financial activities|16|
|Balance sheet|17|
|Statement of cash flows|18|
|Notes to the financial statements|19 - 32|
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 20 2 1. The trustees have adopted the provisions of Accounting and Reporting by Charities: _Statement of Recommended Practice_ applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 201 9 ) and the Charities Act 2016 .
## **OBJECTIVES AND ACTIVITIES**
## **Objectives and aims**
“Improving lives by supporting professionals in the delivery of kidney care and research”
The UK Kidney Association (UKKA) is the leading professional body for the UK kidney community. We welcome members working in clinical renal care, treating and caring for people with kidney disease, those working in research, or related sciences and fields and all allied healthcare professionals.
For decades, the Renal Association (RA) and the British Renal Society (BRS) have been energetic in promoting and sharing research to improve outcomes for people with kidney disease. We have taken a lead in the education of clinicians and scientists and more recently we’ve evolved to take a major role in training doctors and developing clinical services. The last year has seen significant and exciting developments with the bringing together of the British Renal Society and the RA to enable the development of an organisation that represents and supports all healthcare professionals that care for patients with kidney disease. The next few years are expected to see a rapid growth in membership as more of the multi-professional team join the new organisation. A great deal of time has been rightly spent, working in partnership with other charities, shaping the kidney community’s response to the pandemic. Now, even though the workforce will take time to recover, we will concentrate on our mission.
We are transforming the way kidney care and research is delivered in the UK and beyond. Our decisions have been and will continue to be guided by our values :
- Placing patients at the centre of all decisions we make
- Effective representation of our membership and their views
- Celebrating differences and promoting equality
- Working in partnership with those who share our mission
- Equity of access to all services, regardless of professional group
- Ensuring data is accurate and published in the public domain
- Using data to continually drive quality and improvement
- Respecting and developing our staff
- Leading with kindness and compassion
To achieve this, we will value and support all our members from all the professions that make us the UKKA. The UKKA can only be successful if each of the professional groups feel they have a valued place within it. It is also crucial we play our part within the kidney community working with partner charities, both patient and professional facing, along with statutory bodies at a national and regional level. These aims have required new structures and ways of working but are built on firm foundations of good governance including an active and engaged group of trustees, a patient and professional council supporting and shaping strategic decisions along with an experienced executive.
## **ISN Fellowship Program**
The ISN Fellowship Program provides an opportunity for UK units to host trainees from the developing world for up to 12 months. Since 2002, the UK has hosted 53 ISN fellows based in 15 centres through the generous support of the ISN, Kidney Research UK and the UK Kidney Association. There is presently 1 ISN fellow training in Edinburgh.
- 1 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Strategic report Achievements and performance Meetings**
6 to 15 January 2021:
Advanced Nephrology Course, held online
3 to 4 March 2021:
BAPN Winter Meeting, held online
27 to 28 March 2021:
Renal SpR Club Spring Meeting, held online
16 to 17 September 2021: 25 to 26 September 2021: 4 to 7 October 2021:
Renal Pharmacy Group Annual Conference, held online
Renal SpR Club Autumn Meeting, held online
UK Kidney Week 2021, held online
12 to 13 November 2021:
BAPN GRID training days, held at the Orchard DeVere (Nottingham) and online
12 November 2021: Paediatrics Surgical Challenges Meeting, held at Origin Workspace(Bristol) and online
22 November 2021:
Chronic kidney disease: delivering new models of care - A national summit, held at Friends House (London)
Monthly webinars and international case discussions.
## **Renal Association awards and prizes**
## **Medical Student Elective Bursaries**
No Medical Student Elective Bursaries were awarded in 2021.
## **Raine Award**
The Raine award is made annually to a relatively junior member who has made a significant contribution to research. In 2021 the application deadline was extended until January 2022 and this was subsequently awarded to Jennifer Lees.
## **Walls Bursaries**
The John Walls Bursary enables two members, a clinician and non-clinician, to spend short periods at other centres, generally outside the UK, to learn new laboratory techniques or gain new clinical skills. In 2021 no awards were offered.
## **Lockwood Award**
The Lockwood Award is awarded to help members to present work and combine this with a visit to a collaborating laboratory or clinical nephrology unit overseas. In 2021 no awards were offered.
- 2 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Financial review**
## **Where our income came from?**
Our total income for 2021 was £4,223,376 (2020: £3,166,653) an increase of 33%.
Income from charitable activities: The majority of income is sourced from capitation fees which accounted for £2,156,881 (2020: £2,154,702). Other income consists mainly of project work, other income and sponsorship income for events (see note 4). The increase was due to new work for the rare disease registry (RaDaR) and the recognition of this income through the UKKA accounts (previously through the BRS) for the first year. Income from memberships including corporate memberships decreased in 2021 to a total of £ 150 , 641 (2020: £165,727) . Income from scientific meetings increased to £104,791 (2020: £17,786), this was due to the success of the virtual meeting for UK Kidney Week and it's recognition of this income through the UKKA accounts.
Income from donations, legacies and grants increased to £485,362 (2020: £348,609). Due to the merger of the BRS and the RA, the UKKA took responsibility for the grants previously managed by the BRS with Kidney Care UK. This additional income is Kidney Care UK's contribution towards these grants.
Income from investments: Decreased to £7,772 (2020: £11,531).
## **Where was it spent?**
Our total expenditure for 2021 was £3,185,243 (2020: £2,878,008) an increase of 11%. Staff costs increased slightly to £1,948,617 (2020: £1,905,661). The pandemic continued to greatly influence the way we worked and as a result travel and subsistence costs reduced to £24,646 (2020: £42,677). Grants payable increased to £318,345 (2020: £23,805), this was due to the payment of any outstanding BRS grants as discussed under grant income.
For further information please see notes 7-9.
## **Financial position**
The Renal Association had an overall surplus for 2021 of £1,047,985 (2020: £288,470). The association had an overall surplus of £611,488 (2020: deficit of £3,168) and the UK Renal Registry had a surplus of £436,497 (2020: £291,638). At the end of 2021 total assets held by the UKKA were £3,557,430 (2020: £2,509,445).
The British Association of Paediatric Nephrology funds at 31/12/2021 were £23,872 (2020: £35,655).
The Nephrology SpR club funds at 31/12/2021 were £10,670 (2020: £6,617).
Both funds are included within the UKKA unrestricted fund.
- 3 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **COVID-19**
The trustees have considered the impact that the COVID-19 pandemic has had on the charitable company’s current and future financial position. The charitable company has taken the following steps to mitigate the threats that COVID-19 has posed to the organisation:
Action 1 - Reviewed any risk of income due to the possibility of work not being complete d Action 2 - Cancelled some physical meetings and adapted to virtual meetings Action 3 - Analysed any effect on patient numbers (capitation)
The trustees consider that the charitable company will continue as a going concern for a period of at least 18 months from the date on which these financial statements are approved as the trustees of the charity considers that it holds sufficient reserves (as detailed below) to be sustained for the foreseeable future.
The trustees therefore consider it appropriate to adopt the going concern basis for preparation of the accounts, as detailed in note 1.2 to the financial statements.
## **Reserves policy**
The trustees of the UK Kidney Association (UKKA) are obligated to act in the interests of the charity and protect and safeguard the assets with care and skill and in an accountable manner. The reserves policy has been developed by the trustees to explain to the stakeholders why we hold a particular amount of reserves, to demonstrate that finances are being properly managed and provide assurance of our overall resilience and ability to cover the winding up costs of the charity should that become necessary.
The benchmark for 2021 was to hold £3.0 million in reserve. All reserves are held either in short to medium term investments or as cash in hand at the bank. The reserves at 31/12/2021 were £3,557,430 (2020: £2,509,445) which exceeded the benchmark. Overall the UKKA is very secure. The reserves held are sufficient to cover 12 months operating costs and this should be maintained. These reserves held fluctuate throughout the year due to the seasonality of our income however a minimum of one year of staff salaries must be maintained at all times.
## **Investment policy**
The trustees are governed by the Trustee Act 2000 and invest to ensure the best financial return with an acceptable level of risk and whilst still maintaining liquidity. All funds have a minimum credit rating of A- and have an ethical policy which excludes investment in pharmaceutical companies, tobacco companies and companies involved in the production or distribution of alcohol.
- 4 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Organisational development and future plans**
Our mission remains patient focused- “To improve the care of people living with kidney disease by supporting professionals and shaping the delivery of kidney care”
We will achieve this by working in 6 key areas :
## _Developing Leadership:_
- Developing current and future UKKA leaders via a suite of leadership programmes
- Supporting national and regional leadership including national programmes
- Supporting all healthcare professionals who work in kidney services by :
- Optimising the care that they deliver, reducing variations and continuously improving quality
- Setting high standards and enabling comparative audit of patient care and data throug h g uidelines and the UK Renal Registry
- Facilitating training and utilising Quality Improvement methodology supported by KQuIP
## _Research:_
- Working closely with partners within the UK Kidney Research Consortium and beyond
- Promoting and aiding research to reduce the burden of kidney disease and its impact on patients
- Investigating and evaluating services
- Optimising the use of available real-world data to facilitate research
## _Workforce:_
- Monitoring the current and future workforce requirements
- Engaging in shaping the future workforce
- Educating and developing the future workforce in response to technology and other changes working with statutory bodies to shape curriculum as well as delivering our own courses such as;
- UK Kidney Week
- ANC
- Webinars and other annual conferences for differing professional membership groups
## _Education:_
- Provision and facilitation of education to deliver the best possible care for people with kidney disease
- Assisting with undergraduate and postgraduate training through seminars and webinars on latest development, UK Kidney Week, Advanced Nephrology Courses and e-Learning modules
## _Quality Improvement & Assurance:_
- Create and support leadership within renal services by:
- Enabling leaders to shape policy for kidney care services both locally and nationally
- Influencing kidney care nationally and internationally
- Working with colleagues and partners to level up kidney care
- Providing optimal and sustainable kidney care
- Implementing digital solutions and empowering people living with kidney disease to access them
## _Shaping Services:_
- Working with local commissioning services and national policy makers to shape service specifications
- Working with regional commissioning to ensure high standards of care
- Campaigning nationally and locally with partners to raise awareness of kidney disease and the services that prevent and treat it
## **Structure, governance and management Governing document**
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The UK Kidney Association is a company limited by guarantee by its Memorandum and Articles of Association, revised in November 2020. It is registered as a charity with the Charity Commission.
- 5 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Key management remuneration**
The Key Management Personnel of the Charity consists of the Chief Executive Officer and Head of Operations. Where such individuals or those closely connected with them are remunerated by the Charity, their pay is set by a standard salary-band matrix.
## **Related parties**
None of the trustees receive remuneration or other benefits from their work with the charity. As per the amendment in the articles, the payment of reasonable and proper fees to the employer of the President is now permitted. No payments for this time have been made to date. In the current year there were other related party transactions. Kidney Care UK is a related party of The Renal Association due to the shared director of Dr G Lipkin and formerly the late Prof. D O'Donaghue. Related party transactions with Kidney Care UK have been disclosed in note 21.
## **Recruitment and appointment of new trustees**
The Trustees of the Association are appointed in a general meeting and each individual appintment shall be for a term in office as follows:
|**Position**|**Appointed by**|**Term**|**Role**|
|---|---|---|---|
|President|Elected position (ballot
of all members)|Will normally serve for five years in
total; one as President-Elect,
followed by two or three years as
President, followed by two or one
further years as Past President.|Chair of the Trustees. Overall strategic
leadership of the Association, Chair of the
Executive Committee.|
|Past President|See President|See President|Assists the President in carrying out his/her
duties and responsibilities. Chairs Governance
and Nominations Committee and co-ordinates
functions of the Equality, Diversity and
Inclusion Committee|
|President Elect|See President|See President|See President|
|Clinical Vice President x
2|Elected position (ballot
of all members)|Will normally serve for three years
and a maximum of four years.|Chair of the Clinical Affairs Board, which co-
ordinates the joint functions of the: Clinical
Services Committee; Clinical Practice
Guidelines Committee; Patient Information
Committee; Kidney Patient Safety Committee
and the Renal SpR Club.|
|Academic Vice President
x 2|
Elected position (ballot
of all members)|Will normally serve for three years
and a maximum of four years.|Chair of the Academic Affairs Board, which co-
ordinates the joint functions of the:
International Committee, Education and
Training Committee, Research Committee,
Renal Scientists Committee and the Rare
Disease Committee.|
|Honorary Secretary|Appointed by the
trustees|Will normally serve for three years
and a maximum of four years.|Membership enquiries, general enquiries,
communication with the membership, planning
of meetings, preparation of the agenda and
minutes for the Executive and Trustees
meetings, coordinates RA responses to
consultations and works with the Royal College
of Physicians to appoint regional specialist
advisors.|
|Honorary Treasurer|Appointed by the
trustees|Will normally serve for three years
and a maximum of four years|Accounts, contracts, budgeting. Chairs the
Finance and Risk Committee.|
|President of the British
Association for
Paediatric Nephrology
(BAPN)|Elected position (ballot
of all paediatric
members)|Will normally serve for a maximum of
three years.|Chairs Paediatric Affairs Committee.|
|Non-member trustee|Appointed by trustees|Will normally serve for three years
and a maximum of six years|Member of the Finance and Risk Committee
and Governance and Nominations Committee.|
|Appointed member
trustees|Appointed by trustees|Will normally serve for three years
and a maximum of four years|Roles and titles to be appointed by the trustees|
- 6 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Induction and training of new trustees**
Newly elected members are advised of their responsibilities as directors and trustees via a job description. They have a period of hand-over with their predecessor before formally taking up the role.
## **Risk Management**
The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Finance and Risk Committee meet quarterly to review any risks, to ensure our systems are robust and to report on this risk to the trustee board. Good governance is imbedded in our organistation's culture and structure which allows us to react swiftly when necessary.
## **Organisational structure**
Founded in 1950, the UK Kidney Association (formally The Renal Association) is led by the Board of Trustees who work closely with appointed officers and members of the UKKA Council. The board of trustees meets regularly to direct the affairs of the Charity and consult representatives from other related organisations. The Finance & Risk and Governance & Nomination Committees consider their areas of focus in great detail and report recommendations and risks to the Board of Trustees. Development and management of specific clinical and academic activities is delegated to sub-committees who report their proceedings to the Clinical or Academic Affairs Committees.
To view the full structure chart please see: https://ukkidney.org/sites/renal.org/files/UKKA/UKKA%20Structure%2025.06.21.pdf
## **Committees and other bodies**
The Clinical Affairs Board coordinates the activities of the following committees:
|**Committee Name**|**Chair**|
|---|---|
|Clinical Services Committee|Dr Clara Day|
|Clinical Practice Guidelines Committee|Prof James Burton|
|Patient Information Committee|Dr Rebecca Suckling|
|Patient Safety Committee|Dr Katy Jones and Ms
Karen Jenkins|
|Renal SpR Club|Dr Hannah Beckwith|
|Sustainable Kidney Care Committee|Dr Suren
Kanagasundaram/Dr
Rona Hutto n|
|Equality, Diversity and Inclusion Committee|Dr Rebecca Suckling|
The Academic Affairs Board coordinated the activities of the following committees :
|**Committee Name**|**Chair**|
|---|---|
|International Committee|Prof Sunil Bhandari|
|Rare Diseases Committee|Prof Danny Gale|
|Education and Training Committee|Prof Debasish Banerjee|
## **Public Benefit Statement**
The trustees ensure that all activities and future plans are in line with the Renal Association’s aims and that these take into account the Charities Commission’s guidance on public benefit. The trustees confirm that they have complied with the duty in section 17(5) of the Charities Act 2011 to have regard to the Charity Commission's general guidance on public benefit, 'Charities and Public Benefit'. The charitable purposes of the Association are set out in its objectives on page 1.
- 7 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **REFERENCE AND ADMINISTRATIVE DETAILS**
## **Registered Company number**
02229663 (England and Wales)
## **Registered Charity number**
800733
## **Registered office**
Brandon House Building 20a1, Southmead Road, Filton, Bristol, BS34 7RR
- 8 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Trustees**
Prof Paul Cockwell
Professor of Nephrology Consultant Nephrologist Consultant Physiotherapist Consultant Nephrologist Consultant Nephrologist
President Prof Paul Cockwell Professor of Nephrology _(Appointed January 2021)_ Dr Graham Lipkin Consultant Nephrologist _(Previously)_ President BRS Dr Sharlene Greenwood Consultant Physiotherapist _(Appointed August 2021)_ Past President Dr Graham Lipkin Consultant Nephrologist _(Appointed January 2021)_ Prof Donal O’Donoghue Consultant Nephrologist _(Previously)_ Honorary Treasurer Prof Claire Sharpe Professor of Nephrology Honorary Secretary Prof Alan Salama Professor of Nephrology _(Appointed August 2021)_ Dr Indranil Dasgupta Consultant Nephrologist _(Previously)_ Co-Academic Vice President Prof Neil Sheerin Professor of Nephrology Co-Academic Vice President Ms Helen Hurst Consultant Nurse _(Appointed August 2021)_ Co-Clinical Vice President Dr Katie Vinen Consultant Nephrologist _(Appointed January 2021)_ Prof Paul Cockwell Consultant Nephrologist _(Previously)_ Co-Clinical Vice President Ms Karen Jenkins Consultant Nurse _(Appointed August 2021)_ BAPN President Dr Jan Dudley Consultant Paediatric Nephrologist _(Appointed August 2021)_ Dr Sally-Anne Hutton Consultant Paediatric Nephrologist _(Previously)_ Non-member Trustee Mr David Silver Head of European Investment Banking Non-member Trustee Ms Heather Lawrence Chair, London Ambulance Service _(Appointed August 2021)_ NHS Trust
The Company Directors /Trustees met formally four times in 2021 on:19 March; 21 June; 23 September and 6 December 2021. They were additionally in close contact throughout the year, by regular email, telephone communications and scheduled fortnightly Trustee conference calls.
- 9 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Company Secretary**
Prof Alan Salama
## **Auditors**
Haines Watts Bristol Ltd, Bath House, 6-8 Bath Street, Bristol, BS1 6HL The auditors will be proposed for re-appointment at the forthcoming Annual General Meeting.
## **Accountants**
Evans & Partners, 9 Bank Road, Kingswood, Bristol, BS15 8LS The accountants will be proposed for re-appointment at the forthcoming Annual General Meeting
## **Bankers**
Bank of Scotland Metro Bank
## **Solicitors**
Blake Morgan, Bradley Court, Park Place, Cardiff, CF10 3DR
- 10 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) TRUSTEES REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **Statement of Trustees responsibilities**
The trustees (who are also the directors of The Renal Association for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".
Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to select suitable accounting policies and then apply them consistently; observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
In so far as the trustees are aware:
- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.
This report has been prepared in accordance with the special provisions of Part 15 of Companies Act 2006 relating to small companies.
Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on .................... and signed on the board's behalf by:
..............................
## **Professor Claire Sharpe**
- 11 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) INDEPENDENT AUDITOR'S REPORT**
## **TO THE TRUSTEES OF THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION**
## **Opinion**
We have audited the financial statements of The Renal Association (the 'charitable company') for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In our opinion, the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 December 20 21 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Companies Act 2006.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
## **Material uncertainties relating to going concern**
We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:
- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.
## **Other information**
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.
Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
- 12 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) INDEPENDENT AUDITOR'S REPORT (CONTINUED)**
## **TO THE TRUSTEES OF THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION**
## **Opinions on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of our audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.
## **Matters on which we are required to report by exception**
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.
## **Responsibilities of trustees**
As explained more fully in the Trustees' Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.
- 13 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) INDEPENDENT AUDITOR'S REPORT (CONTINUED)**
## **TO THE TRUSTEES OF THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION**
## **Our responsibilities for the audit of the financial statements**
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities outlined above, to detect material misstatements in respect of irregularities, including fraud. We obtained an understanding of the legal and regulatory framework applicable to the charitable company, including those areas that could reasonably be expected to have a material effect on the financial statements. The most significant were identified as The Companies Act 2006, UK GAAP (FRS102), The Charities SORP (FRS102) and The Charities Act 2011.
We considered the extent of compliance with those laws and regulations as part of our procedures on the related financial statements. Our audit procedures included:
- Making enquiries of management in respect to the susceptibility and suspicion of fraud;
- Obtaining an understanding of the internal control structure;
- Closely examining significant unusual transactions outside the charitable company's normal activities;
- Substantive testing on journal entries for any signs of manipulation;
- Detailed review of accounting estimates;
- Agreeing a sample of employee's details to payroll/HR records and contracts;
- Substantively testing the recognition and completeness of the charitable company's income streams; and
- Testing the allocation of income and expenditure to the correct funds of the charitable company.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.
- 14 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) INDEPENDENT AUDITOR'S REPORT (CONTINUED)**
## **TO THE TRUSTEES OF THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION**
## **Use of our report**
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Matthew Bracher BSc FCA (Senior Statutory Auditor) for and on behalf of Haines Watts Bristol Limited Chartered Accountants and Statutory Auditors Bath House 6-8 Bath Street Bristol BS1 6HL
Date: .........................
- 15 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**Unrestricted Designated**
**funds**
**funds**
**Notes**
**£**
**£**
**Income and endowments from:**
Donations, legacies and grants
**2**
205,728
279,634
Charitable activities
**3**
529,560
2,861,361
Investments
**5**
31
7,741
Other income
**6**
349,321
-
**Total income**
1,084,640
3,148,736
**Expenditure on:**
Charitable activities
Expenditure of charitable activities
**7**
473,152
2,712,091
**Net income for the year/**
**Net incoming resources**
611,488
436,645
**Other recognised gains and losses**
Other gains or losses
**12**
-
(148)
**Net movement in funds**
611,488
436,497
Fund balances at 1 January 2021
216,808
2,292,637
**Fund balances at 31 December 2021**
828,296
2,729,134|**Total**
**2021**
**£**
485,362
3,390,921
7,772
349,321
4,233,376
3,185,243
1,048,133
(148)
1,047,985
2,509,445
3,557,430|**Total**
**2020**
**£**
348,609
2,806,513
11,531
-
3,166,653
2,878,008
288,645
(175)
288,470
2,220,975
2,509,445|
|---|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.
The movement in reserves related to the merger of the the Renal Pharmacy Group and the British Renal Society into The Renal Association.
- 16 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) BALANCE SHEET**
## _**AS AT 31 DECEMBER 2021**_
|**Unrestricted**
**Designated**
**funds**
**funds**
**Notes**
**£**
**£**
**Fixed assets**
Tangible assets
**14**
697
34,613
**Current assets**
Debtors
**15**
182,018
615,178
Cash at bank and in hand
796,773
2,352,979
978,791
2,968,157
**Creditors: amounts falling due within**
**one year**
**16**
(94,910)
(329,918)
Net current assets
883,881
2,638,239
**Total assets less current liabilities**
884,578
2,672,852
**Income funds**
Designated funds
Unrestricted funds|**2021**
**Total**
**funds**
**£**
35,310
797,196
3,149,752
3,946,948
(424,828)
3,522,120
3,557,430
2,729,134
828,296
3,557,430|**2020**
**Total**
**funds**
**£**
50,193
725,667
2,097,872
2,823,539
(364,287)
2,459,252
2,509,445
2,292,637
216,808
2,509,445|
|---|---|---|
The trustees responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements , so far as applicable to the company.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the Trustees on .........................
..............................
Professor Claire Sharpe **Trustee**
## **Company Registration No. 02229663**
- 17 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) STATEMENT OF CASH FLOWS**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**Notes**
**Cash flows from operating activities**
Cash generated from operations
**22**
**Cash flows from investing activities**
Purchase of tangible fixed assets
Interest received
**Net cash generated from investing**
**activities**
**Net increase in cash and cash equivalents**
Cash and cash equivalents at beginning of year
**Cash and cash equivalents at end of year**
**Notes to the Cash Flow Statement**
1. Analysis of changes in net debt
**Net cash**
Cash at bank and in hand
**Total**|**2021**
**£**
**£**
1,050,010
(5,902)
7,772
1,870
1,051,880
2,097,872
3,149,752
At 1/1/21
2,097,872
2,097,872|**2020**
**£**
**£**
25,362
(4,430)
11,531
7,101
32,463
2,065,409
2,097,872
Cash flow
At 31/12/21
1,051,880
3,149,752
1,051,880
3,149,752|
|---|---|---|
- 18 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **1 Accounting policies**
## **Charity information**
The Renal Association is a private company limited by guarantee incorporated in England and Wales. The registered office is Brandon House Building 20a1 , Southmead Road, Bristol, BS34 7RR.
## **1.1 Accounting convention**
The financial statements of the charitable company, which is a public benefit entity under FRS102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.
The financial statements are prepared in sterling , which is the functional currency of the Renal Association . Monetary a mounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention.The principal accounting policies adopted are set out below.
## **1.2 Going concern**
The accounts have been prepared on the assumption that the charitable company is able to continue as a going concern. The financial statements have been prepared on a going concern basis after consideration by the Trustees of the potential impact of COVID-19.
The trustees have considered the impact of this issue on the current and future financial position. The charitable company holds unrestricted, general reserves of £828,296, designated reserves that can be drawn down if necessary of £2,729,134 and a cash balance of £3,149,752. The trustees consider that the charitable company has sufficient cash reserves to continue as a going concern for a period of at least 12 months from the date on which these financial statements are approved.
The Trustees have tested their cash flow analysis to take into account the impact on the charitable company of possible scenarios brought on by the impact of COVID-19, alongside the measures that they can take to mitigate the impact.
## **1.3 Charitable funds**
Unrestricted funds are used in accordance with the charitable objectives at the discretion of the trustees.
Certain funds will be designated for specific purposes. The Executive Committee have decided that setting aside funds in this way is a useful financial discipline which will help the charity make the best use of its resources, even though there is no legal force to the designation.
Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in note 17 (movement in funds).
## **1.4 Income**
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. Full provision is made for subscriptions received in advance. All voluntary income is included in income on a receipt basis.
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes. Capitation fees and grants are recognised on a receivable basis. Scientific meetings are recognised on a receipt basis when tickets for a course or event are purchased.
During the year, the assets transferred from the BRS and the Renal Pharmacy Group have been included in other income and have been allocated to the relevant balance sheet items.
- 19 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **1 Accounting policies**
## **(Continued)**
## **1.5 Expenditure**
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.
## **1.6 Tangible fixed assets**
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Computer equipment 33% on cost Fixtures and fittings 25% on cost
Fixed assets are capitalised when the initial cost exceeds £500.
## **1.7 Financial instruments**
The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## _**Basic financial assets**_
Basic financial assets, which include trade and other debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost. Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the charity transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
## _**Basic financial liabilities**_
Basic financial liabilities, including trade and other creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method. Financial liabilities are derecognised when, and only when, the charity's contractual obligations are discharged, cancelled, or they expire.
## **1.8 Taxation**
The charity is exempt from corporation tax on its charitable activities.
- 20 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **1 Accounting policies**
## **(Continued)**
## **1.9 Employee benefits**
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
## **1.10 Retirement benefits**
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
## **1.11 Leases**
Rentals payable and receivable under operating leases are charges to the SoFA on a straight line basis over the period of the lease.
## **1.12 Foreign exchange**
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure ) for the period.
## **2 Donations, legacies and grants**
|**Unrestricted Designated**
**funds**
**funds**
**£**
**£**
Grants
204,845
279,634
Donations
883
-
205,728
279,634
Grants received, included in the above are as follows:
Renal Association Unrestricted
Renal Registry Designated|**Total**
**2021**
**£**
484,479
883
485,362
**2021**
**£**
204,845
279,634
484,479|**Total**
**2020**
**£**
348,526
83
348,609
**2020**
**£**
-
348,526
348,526|
|---|---|---|
- 21 -
## **THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE)**
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **3 Income from charitable activities**
|**Capitation fees**
**- Renal**
**Registry**
**Subscriptions**
**- Renal**
**Association**
**Scientific**
**meetings -**
**Renal**
**Association**
**Other income -**
**Renal**
**Association**
**Other income -**
**Renal Registry**
**(See note 4)**
**(See note 4)**
**£**
**£**
**£**
**£**
**£**
Income from charitable activities
2,156,881
150,641
104,791
274,128
704,480
Analysis by fund
Unrestricted funds
-
150,641
104,791
274,128
-
Designated funds
2,156,881
-
-
-
704,480
2,156,881
150,641
104,791
274,128
704,480
**For the year ended 31 December 2020**
Unrestricted funds
-
165,727
17,786
23,629
-
Designated funds
2,154,702
-
-
-
444,669
2,154,702
165,727
17,786
23,629
444,669|**Total**
**2021**
**£**
3,390,921
529,560
2,861,361
3,390,921|**Total**
**2020**
**£**
2,806,513
207,142
2,599,371
2,806,513|
|---|---|---|
- 22 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **4 Other charitable activity income**
|**Unrestricted Designated**
**funds**
**funds**
**2021**
**2021**
**£**
**£**
Events
216,475
-
Cross charge
-
82,523
Project fees
-
98,459
Other income
57,653
523,498
Other income
274,128
704,480
**Investments**
**Unrestricted Designated**
**funds**
**funds**
**£**
**£**
Interest receivable
31
7,741|**Total**
**2021**
**£**
216,475
82,523
98,459
581,151
978,608
**Total**
**2021**
**£**
7,772|**Total**
**2020**
**£**
-
91,543
159,142
217,613
468,298
**Total**
**2020**
**£**
11,531|
|---|---|---|
## **5 Investments**
## **6 Other income**
During the year there was a transfer of assets totalling £349,321 relating to two entities. The assets transferred was as follows:
|**Renal Pharmacy**
**Group**
**British Renal**
Assets
64,646
Liabilities
-
Total
64,646|**Society**
284,675
-
284,675|
|---|---|
- 23 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **7 Charitable activities costs**
|Direct costs Grant funding
of activities
(See note 8)
Support costs
(See note 9)
£
£
£
Expenditure of Charitable activities
33,200
318,345
2,833,698
**8**
**Grants payable**
The total grants paid to individuals during the year was as follows:
2021
£
Individual grants
318,345|Totals
£
3,185,243
2020
£
23,805|
|---|---|
- 24 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**9**
**Support Costs**
Management
£
Expenditure of Charitable activities
1,948,617
Human
recources
£
Expenditure of Charitable activities
24,646
Expenditure of Charitable activities
Support costs, included in the above, are as follows:
**Management**
Trustees' expenses
Wages
Social security
Pensions
Training and Development
**Finance**
Bank charges
**Information technology**
Computer,storage & advertising|Finance
Information
technology
£
£
1,709
278,157
Other
Governance
costs
£
£
137,679
442,891
Total
£
2,833,698
**2021**
**2020**
**£**
**£**
-
1,267
1,663,447
1,649,651
155,868
149,578
89,355
82,845
39,947
22,320
1,948,617
1,905,661
**2021**
**2020**
**£**
**£**
1,709
1,049
**2021**
**2020**
**£**
**£**
278,157
262,988|
|---|---|
- 25 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**9**
**Support Costs**
**Human resources**
Travelling & Subsistance
**Other**
Office Costs
Postage and stationery
Depreciation of tangible fixed assets
Bad debt
**Governance costs**
Auditors' remuneration
Legal and professional
Secretarial fees
Accountancy and legal|**(Continued)**
**2021**
**2020**
**£**
**£**
24,646
42,677
**2021**
**2020**
**£**
**£**
112,436
122,659
3,765
5,828
20,784
20,322
694
(667)
137,679
148,141
**2021**
**2020**
**£**
**£**
5,600
4,700
322,427
312,890
103,791
107,852
11,073
9,788
442,891
435,230|
|---|---|
## **10 Trustees' remuneration and benefits**
None of our trustees receive remuneration or other benefit from their work with the charity. Please see https://renal.org/trustee-declarations-interest/ for other declarations of interests. Trustees expenses are paid with accordance to The Renal Association expense claim policy. In 20 2 1 4 trustees were reimbursed expenses totaling £751 (2020: £2,079 reimbursed to 3 trustees ).
- 26 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **11 Employees**
## **Number of employees**
The average monthly number employees during the year was:
|**Employment costs**
Wages and salaries
Social security costs
Other pension costs
The number of employees whose annual remuneration was £60,000 or
more were:
Employees earning over £60,000
**12**
**Other gains or losses**
**Unrestricted Designated**
**funds**
**funds**
**£**
**£**
Foreign exchange losses
-
148
**For the year ended 31**
**December 2020**
17
158|**2021**
**Number**
38
**2021**
**£**
1,663,447
155,868
89,355
1,908,670
**2021**
**Number**
2
**Total**
**2021**
**£**
148|**2020**
**Number**
37
**2020**
**£**
1,649,651
149,578
82,845
1,882,074
**2020**
**Number**
2
**Total**
**2020**
**£**
175
175|
|---|---|---|
||||
||||
- 27 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
_**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **13 STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2020**
|**Unrestricted**
**Designated**
**funds**
**funds**
**£**
**£**
**Income from:**
Donations and legacies
83
348,526
Charitable activities
207,142
2,599,371
Investments
192
11,339
**Total income**
207,417
2,959,236
**Expenditure on:**
**Charitable activities**
Expenditure of Charitable activities
210,568
2,667,440
Other recognised gains and losses
17
158
**Net Income/(Expenditure)**
(3,168)
291,638
**Reconciliation of funds**
**Total funds brought forward**
219,976
2,000,999
**Total funds carried forward**
216,808
2,292,637
**14**
**Tangible fixed assets**
**Computer**
**equipment**
**Fixtures and**
**fittings**
**£**
**£**
**Cost**
At 1 January 2021
92,590
59,454
Additions
5,902
-
At 31 December 2021
98,492
59,454
**Depreciation and impairment**
At 1 January 2021
82,261
19,590
Depreciation charged in the year
6,715
14,070
At 31 December 2021
88,976
33,660
**Carrying amount**
At 31 December 2021
9,516
25,794
At 31 December 2020
10,329
39,864|**Total**
**funds**
**£**
348,609
2,806,513
11,531
3,166,653
2,878,008
175
288,470
2,220,975
2,509,445
**Total**
**£**
152,044
5,902
157,946
101,851
20,785
122,636
35,310
50,193|
|---|---|
- 28 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**15**
**Debtors**
**Amounts falling due within one year:**
Trade debtors
Other debtors
Prepayments and accrued income
**16**
**Creditors: amounts falling due within one year**
Other taxation and social security
Trade creditors
Other creditors
Accruals and deferred income|**2021**
**£**
623,829
-
173,368
797,196
**2021**
**£**
54,784
5,396
47,830
316,818
424,828|**2020**
**£**
495,701
12,720
217,247
725,667
**2020**
**£**
41,457
95,793
46,020
181,017
364,287|
|---|---|---|
- 29 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
|**17**
**Movement in funds**
**Unrestricted funds**
Renal Association
**Designated funds**
Renal Registry
**Total funds**
Net movement in funds, included in the
**Unrestricted funds**
Renal Association
**Designated funds**
Renal Registry
Total funds
**Designated Funds**
**Renal Registry Designated**
**Total Designated Funds**
**Funds**|At 1/1/21 Net movement
in funds
At 31/12/21
£
£
£
216,808
611,488
828,296
2,292,637
436,497 2,729,134
2,509,445
1,047,985 3,557,430
above are as follows:
Incoming
resources
Resources
expended
Mergers Movement
in funds
£
£
£
£
735,319
(473,152)
349,321
611,488
3,148,736
(2,712,239)
-
436,497
3,884,055
(3,185,391)
349,321 1,047,985
Brought
forward
Incoming
resources
Resources
expended
Transfers
Carried
Forward
£
£
£
£
£
2,292,637
3,148,736
(2,712,239)
- 2,729,134
2,292,637
3,148,736
(2,712,239)
- 2,729,134|
|---|---|
## **Renal Association Fund**
This fund represents the free reserves of the charity.
## **Renal Registry Fund**
This fund represents amounts which are committed to the UK Renal Registry and have been set aside by the Executive Committee to help the charity make best use of its resources.
- 30 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **18 Retirement benefit schemes**
## **Defined contribution schemes**
The operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the in an independently administered fund.
The charge to profit or loss in respect of defined contribution schemes was £89,355 (2020 : £82,845).
At the year end there were pensions of £12,507 (2020: £12,284) deducted from salaries but not yet paid over to the pension scheme administrator.
## **19 Share capital**
The charitable company is limited by guarantee and therefore has no share capital. Each member's guarantee is limited to £1.
## **20 Operating lease commitments**
The following operating lease payments are committed to be paid as follows:
|Within one year
Between two and five years
In over five years|**Land and buildings**
**2021**
**2020**
**£**
**£**
48,000
42,075
192,000
192,000
136,000
184,000
376,000
418,075|
|---|---|
- 31 -
**THE RENAL ASSOCIATION T/A THE UK KIDNEY ASSOCIATION (A COMPANY LIMITED BY GUARANTEE) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2021**_
## **21 Related party transactions**
Payments made to University Hospital Birmingham Trust relating to the GIRFT programme totaled £91,133.22 (2020: £0), a related party due to its employment of two trustees (Dr Lipkin and Prof Cockwell).
During the year, the UK Kidney Association was paid by Kidney Care UK, a related party due to the shared director Dr Graham Lipkin, £374,122 (2020: £186,586) of which:
- £194,051 was for the KQuIP, PREM and patient leaflets programmes, (2020: £166,586)
- £179,846 was for the BRS grants (2020: £0)
- £225 was for UK Kidney Week registration, (2020: £0)
- £0 for the Home Therapies programme, (2020: £20,000)
At 31/12/2021 the UK Kidney Association held £0 (2020: £7,812) on behalf of Kidney Care UK in relation to grants payable.
## **Remuneration of key management personnel**
The remuneration of key management personnel is as follows.
|Aggregate compensation
**22**
**Cash generated from operations**
Surplus for the year
Adjustments for:
Investment income recognised in statement of financial activities
Foreign exchange differences
Depreciation and impairment of tangible fixed assets
Movements in working capital:
(Increase) in debtors
Increase in creditors
**Cash generated from operations**|**2021**
**£**
248,443
**2021**
**£**
1,048,133
(7,772)
(148)
20,785
(71,529)
60,541
1,050,010|**2020**
**£**
252,251
**2020**
**£**
288,645
(11,532)
(175)
20,322
(343,321)
71,422
25,362|
|---|---|---|
- 32 -